<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362594</url>
  </required_header>
  <id_info>
    <org_study_id>3475-054</org_study_id>
    <secondary_id>1325-MG</secondary_id>
    <secondary_id>2014-004944-37</secondary_id>
    <secondary_id>163277</secondary_id>
    <secondary_id>KEYNOTE-054</secondary_id>
    <secondary_id>MK-3475-054</secondary_id>
    <nct_id>NCT02362594</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)</brief_title>
  <official_title>Adjuvant Immunotherapy With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-risk Stage III Melanoma: A Randomized, Double- Blind Phase 3 Trial of the EORTC Melanoma Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whether post-surgery therapy with pembrolizumab improves
      recurrence-free survival (RFS) as compared to placebo for high-risk participants with
      melanoma (Stage IIIA [&gt; 1 mm metastasis], IIIB and IIIC). The study will also assess whether
      pembrolizumab improves RFS versus placebo in the subgroup of participants with programmed
      cell death-ligand 1 (PD-L1)-positive tumor expression. Participants will be stratified for
      stage of disease and region and then will be randomly assigned to receive either
      pembrolizumab or placebo as post-surgery therapy in Part 1. In Part 2, participants who
      experience a disease recurrence are eligible for pembrolizumab treatment (if treated with
      placebo in Part 1) or pembrolizumab rechallenge (if treated with pembrolizumab in Part 1).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 16, 2015</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Actual">January 8, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among All Participants</measure>
    <time_frame>6 months</time_frame>
    <description>RFS was defined as the time between the date of randomization and the date of first melanoma recurrence (local, regional, distant metastasis) or death (whatever the cause), whichever occurred first. For participants who remained alive and whose disease had not recurred, RFS was censored on the date of last visit/contact with disease assessments. The percentage of participants with RFS at Month 6 was reported for all participants in both treatment arms of Part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among Participants With PD-L1-positive Tumor Expression</measure>
    <time_frame>6 months</time_frame>
    <description>RFS was defined as the time between the date of randomization and the date of first melanoma recurrence (local, regional, distant metastasis) or death (whatever the cause), whichever occurred first. For participants who remained alive and whose disease had not recurred, RFS was censored on the date of last visit/contact with disease assessments. The percentage of participants with RFS at Month 6 was reported for all participants with PD-L1-positive tumors in both treatment arms of Part 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant Metastases-free Survival (DMFS) in All Participants</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>DMFS will be defined as the time between the date of randomization and the date of first distant metastasis or date of death (whatever the cause), whichever occurs first. For participants who remain alive and distant metastasis-free, DMFS will be censored on the date of last visit/contact with disease assessments. The percentage of participants with DMFS will be reported for all participants in both treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastases-free Survival (DMFS) for Participants With PD-L1-positive Tumor Expression</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Description:
DMFS will be defined as the time between the date of randomization and the date of first distant metastasis or date of death (whatever the cause), whichever occurs first. For participants who remain alive and distant metastasis-free, DMFS will be censored on the date of last visit/contact with disease assessments. The percentage of participants with DMFS will be reported for all participants with PD-L1-positive tumors in both treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) for All Participants</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>OS will be defined as the time from the date of randomization to the date of death, whatever the cause. The follow-up of participants still alive will be censored at the moment of last visit/contact. OS will be reported for all participants in both treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) for Participants With PD-L1-positive Tumor Expression</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>OS will be defined as the time from the date of randomization to the date of death, whatever the cause. The follow-up of participants still alive will be censored at the moment of last visit/contact. OS will be reported for all participants with PD-L1-positive tumors in both treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced At Least 1 Adverse Event (AE)</measure>
    <time_frame>Up to 22 months</time_frame>
    <description>An AE is defined as &quot;any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment&quot;. An AE can therefore be any unfavorable and unintended signs (such as rash or enlarged liver), symptoms (such as nausea or chest pain), an abnormal laboratory finding (including results of blood tests, x-rays or scans) or a disease temporarily associated with the use of the protocol treatment, whether or not considered related to the investigational medicinal product. The number of participants who experienced at least 1 AE was reported for all participants in each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)</measure>
    <time_frame>Up to 22 months</time_frame>
    <description>An AE is defined as &quot;any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment&quot;. An AE can therefore be any unfavorable and unintended signs (such as rash or enlarged liver), symptoms (such as nausea or chest pain), an abnormal laboratory finding (including results of blood tests, x-rays or scans) or a disease temporarily associated with the use of the protocol treatment, whether or not considered related to the investigational medicinal product. The number of participants who discontinued study treatment due to an AE was reported for all participants in each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of Pembrolizumab</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and then Day 1 of cycle for every 4 cycles afterwards (up to approximately 16 months). Each cycle is 3 weeks.</time_frame>
    <description>Blood samples were to be collected at pre-specified time points and plasma isolated for analysis of pembrolizumab CL, defined as the volume of plasma from which pembrolizumab is eliminated per unit time following IV pembrolizumab administration. Samples were not collected and this analysis was not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (V) of Pembrolizumab</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and then Day 1 of cycle for every 4 cycles afterwards (up to approximately 16 months). Each cycle is 3 weeks.</time_frame>
    <description>Blood samples were to be collected at pre-specified time points and plasma isolated for analysis of pembrolizumab V, defined as the theoretical volume that would be necessary to contain the total amount of administered pembrolizumab at the same concentration that it is observed in the blood plasma. Samples were not collected and this analysis was not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Positive for Anti-Drug Antibodies (ADA) After Pembrolizumab Treatment</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and then Day 1 of cycle for every 4 cycles afterwards (up to approximately 16 months). Each cycle is 3 weeks.</time_frame>
    <description>Pre- and post-baseline serum samples from participants treated with pembrolizumab were analyzed for ADA by means of a neutralizing antibody assay which assessed the ability of ADA to block (neutralize) binding of pembrolizumab to Programmed Cell Death-1 (PD-1) protein. Overall immunogenicity was defined as the number of treatment emergent positive participants based on the total number of evaluable participants (treatment emergent positive, non-treatment emergent positive and negative immunogenicity status).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1019</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1, participants receive pembrolizumab 200 mg intravenously (IV) as post-surgery therapy every 3 weeks (Q3W) for up to 1 year. During Part 2, participants with documented recurrence may receive optional re-treatment with pembrolizumab Q3W for up to 2 years or disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Part 1, participants receive placebo IV as post-surgery therapy Q3W. During Part 2, participants with documented recurrence who received placebo in Part 1 may receive optional treatment with pembrolizumab Q3W for up to 2 years or disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Normal saline solution administered IV on Day 1 of each 21-day cycle</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Completely resected Stage III melanoma

          -  Tumor tissue available for evaluation of PD-L1 expression

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate organ function

          -  No prior therapy for melanoma except surgery for primary melanoma lesions (or
             previously treated with interferon for thick primary melanomas without evidence of
             lymph node involvement are eligible)

          -  Female participants of childbearing potential should be willing to use adequate
             methods of birth control or be surgically sterile, or abstain from heterosexual
             activity for the course of the study through 120 days after the last dose of study
             medication

          -  Male participants should agree to use an adequate method of birth control starting
             with the first dose of study therapy through 120 days after the last dose of study
             medication

        Exclusion criteria:

          -  Mucosal or ocular melanoma

          -  History of (non-infectious) pneumonitis that required steroids or current pneumonitis

          -  History of or current interstitial lung disease

          -  History of hematologic or primary solid tumor malignancy, unless no evidence of that
             disease for 5 years

          -  Active autoimmune disease that has required systemic treatment in past 2 years

          -  Active infection requiring therapy

          -  Unstable hyperthyroidism or hypothyroidism

          -  Diagnosis of immunodeficiency

          -  Systemic steroid therapy or any other form of immunosuppressive therapy within 7 days
             prior to the first dose of study medication

          -  Known history of human immunodeficiency virus (HIV), active Hepatitis B or C

          -  Treatment with live vaccine within 30 days prior to the first dose of study medication
             are not eligible

          -  Prior treatment with any anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
             monoclonal antibody or anti-programmed cell death receptor 1 (PD-1), anti-programmed
             cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2
             (PD-L2) agent, or prior participation in any Merck pembrolizumab clinical trial

          -  Currently participating and receiving study therapy, or participated in a study of an
             investigational agent and received study therapy or used an investigation device
             within 4 weeks of the first dose of study medication

          -  Pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 120 days
             after the last dose of study medication

          -  Participant is or has an immediate family member (e.g., spouse, parent/legal guardian,
             sibling or child) who is investigational site or Sponsor staff directly involved with
             this trial without prospective Institutional Review Board approval (by chair or
             designee) is given
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2015</study_first_posted>
  <results_first_submitted>December 10, 2018</results_first_submitted>
  <results_first_submitted_qc>December 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 4, 2019</results_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD-1)</keyword>
  <keyword>Programmed Cell Death 1 (PD1)</keyword>
  <keyword>Programmed Cell Death-Ligand 1 (PD-L1, PDL1)</keyword>
  <keyword>Programmed Cell Death-Ligand 2 (PD-L2, PDL2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02362594/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>As of the 02-Oct-2017 interim database cut-off date, of the 1019 randomized participants in Part 1, 544 had completed Part 1 and 62 were continuing in Part 1. This interim results disclosure is for Part 1 only.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pembrolizumab</title>
          <description>In Part 1, participants received pembrolizumab 200 mg intravenously (IV) as post-surgery therapy every 3 weeks (Q3W) for up to 1 year.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>In Part 1, participants received placebo IV as post-surgery therapy Q3W.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="514"/>
                <participants group_id="P2" count="505"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="509"/>
                <participants group_id="P2" count="502"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Continuing Part 1 Adjuvant Therapy</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="264"/>
                <participants group_id="P2" count="280"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="225"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pembrolizumab</title>
          <description>In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>In Part 1, participants received placebo IV as post-surgery therapy Q3W.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="514"/>
            <count group_id="B2" value="505"/>
            <count group_id="B3" value="1019"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="514"/>
                    <count group_id="B2" value="505"/>
                    <count group_id="B3" value="1019"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="13.6"/>
                    <measurement group_id="B2" value="53.7" spread="14.2"/>
                    <measurement group_id="B3" value="53.8" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="514"/>
                    <count group_id="B2" value="505"/>
                    <count group_id="B3" value="1019"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="391"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="324"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Programmed Death-Ligand 1 (PD-L1) Tumor Status</title>
          <description>Tumor PD-L1 status was assessed by immunohistochemistry (IHC) and recorded as positive (≥1% PD-L1 IHC), negative (&lt;1% PD-L1 IHC), or undetermined level of expression (indeterminate PD-L1 IHC).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>PD-L1 Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="514"/>
                    <count group_id="B2" value="505"/>
                    <count group_id="B3" value="1019"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="428"/>
                    <measurement group_id="B2" value="425"/>
                    <measurement group_id="B3" value="853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD-L1 Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="514"/>
                    <count group_id="B2" value="505"/>
                    <count group_id="B3" value="1019"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undetermined</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="514"/>
                    <count group_id="B2" value="505"/>
                    <count group_id="B3" value="1019"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Melanoma Stage</title>
          <description>Participants were stratified by melanoma stage using the American Joint Committee on Cancer (AJCC) 7th edition stage as follows: Stage IIIA (with &gt;1 mm metastasis), Stage IIIB, Stage IIIC with 1-3 positive lymph nodes (LN+), and Stage IIIC with ≥4 LN+.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Stage IIIA (&gt; 1 mm)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="514"/>
                    <count group_id="B2" value="505"/>
                    <count group_id="B3" value="1019"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IIIB</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="514"/>
                    <count group_id="B2" value="505"/>
                    <count group_id="B3" value="1019"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IIIC (1-3 LN+)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="514"/>
                    <count group_id="B2" value="505"/>
                    <count group_id="B3" value="1019"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IIIC (≥4 LN+)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="514"/>
                    <count group_id="B2" value="505"/>
                    <count group_id="B3" value="1019"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="514"/>
                    <count group_id="B2" value="505"/>
                    <count group_id="B3" value="1019"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>North America</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                    <measurement group_id="B2" value="336"/>
                    <measurement group_id="B3" value="677"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Australia/New Zealand</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among All Participants</title>
        <description>RFS was defined as the time between the date of randomization and the date of first melanoma recurrence (local, regional, distant metastasis) or death (whatever the cause), whichever occurred first. For participants who remained alive and whose disease had not recurred, RFS was censored on the date of last visit/contact with disease assessments. The percentage of participants with RFS at Month 6 was reported for all participants in both treatment arms of Part 1.</description>
        <time_frame>6 months</time_frame>
        <population>All randomized participants in Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Part 1, participants received placebo IV as post-surgery therapy Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among All Participants</title>
          <description>RFS was defined as the time between the date of randomization and the date of first melanoma recurrence (local, regional, distant metastasis) or death (whatever the cause), whichever occurred first. For participants who remained alive and whose disease had not recurred, RFS was censored on the date of last visit/contact with disease assessments. The percentage of participants with RFS at Month 6 was reported for all participants in both treatment arms of Part 1.</description>
          <population>All randomized participants in Part 1.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
                <count group_id="O2" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" lower_limit="78.6" upper_limit="85.3"/>
                    <measurement group_id="O2" value="73.3" lower_limit="69.2" upper_limit="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of RFS time-to-event distribution between the 2 treatment arms was based on Cox regression model with treatment as a covariate stratified by stage (IIIA [&gt;1 mm metastasis] vs. IIIB vs. IIIC 1-3 nodes vs. IIIC ≥4 nodes) as indicated at randomization.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>One-sided p-value based on log-rank test.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.57</param_value>
            <ci_percent>98.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among Participants With PD-L1-positive Tumor Expression</title>
        <description>RFS was defined as the time between the date of randomization and the date of first melanoma recurrence (local, regional, distant metastasis) or death (whatever the cause), whichever occurred first. For participants who remained alive and whose disease had not recurred, RFS was censored on the date of last visit/contact with disease assessments. The percentage of participants with RFS at Month 6 was reported for all participants with PD-L1-positive tumors in both treatment arms of Part 1.</description>
        <time_frame>6 months</time_frame>
        <population>All randomized participants in Part 1 with PD-L1-positive tumors.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Part 1, participants received placebo IV as post-surgery therapy Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among Participants With PD-L1-positive Tumor Expression</title>
          <description>RFS was defined as the time between the date of randomization and the date of first melanoma recurrence (local, regional, distant metastasis) or death (whatever the cause), whichever occurred first. For participants who remained alive and whose disease had not recurred, RFS was censored on the date of last visit/contact with disease assessments. The percentage of participants with RFS at Month 6 was reported for all participants with PD-L1-positive tumors in both treatment arms of Part 1.</description>
          <population>All randomized participants in Part 1 with PD-L1-positive tumors.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8" lower_limit="80.0" upper_limit="87.0"/>
                    <measurement group_id="O2" value="75.4" lower_limit="71.0" upper_limit="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of RFS time-to-event distribution between the 2 treatment arms (PD-L1-positive participants) was based on Cox regression model with treatment as a covariate stratified by stage (IIIA [&gt;1 mm metastasis] vs. IIIB vs. IIIC 1-3 nodes vs. IIIC ≥4 nodes) as indicated at randomization.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>One-sided p-value based on log-rank test.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95.0</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distant Metastases-free Survival (DMFS) in All Participants</title>
        <description>DMFS will be defined as the time between the date of randomization and the date of first distant metastasis or date of death (whatever the cause), whichever occurs first. For participants who remain alive and distant metastasis-free, DMFS will be censored on the date of last visit/contact with disease assessments. The percentage of participants with DMFS will be reported for all participants in both treatment arms.</description>
        <time_frame>Up to 10 years</time_frame>
        <posting_date>07/2026</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distant Metastases-free Survival (DMFS) for Participants With PD-L1-positive Tumor Expression</title>
        <description>Description:
DMFS will be defined as the time between the date of randomization and the date of first distant metastasis or date of death (whatever the cause), whichever occurs first. For participants who remain alive and distant metastasis-free, DMFS will be censored on the date of last visit/contact with disease assessments. The percentage of participants with DMFS will be reported for all participants with PD-L1-positive tumors in both treatment arms.</description>
        <time_frame>Up to 10 years</time_frame>
        <posting_date>07/2026</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) for All Participants</title>
        <description>OS will be defined as the time from the date of randomization to the date of death, whatever the cause. The follow-up of participants still alive will be censored at the moment of last visit/contact. OS will be reported for all participants in both treatment arms.</description>
        <time_frame>Up to 10 years</time_frame>
        <posting_date>07/2026</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) for Participants With PD-L1-positive Tumor Expression</title>
        <description>OS will be defined as the time from the date of randomization to the date of death, whatever the cause. The follow-up of participants still alive will be censored at the moment of last visit/contact. OS will be reported for all participants with PD-L1-positive tumors in both treatment arms.</description>
        <time_frame>Up to 10 years</time_frame>
        <posting_date>07/2026</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced At Least 1 Adverse Event (AE)</title>
        <description>An AE is defined as &quot;any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment&quot;. An AE can therefore be any unfavorable and unintended signs (such as rash or enlarged liver), symptoms (such as nausea or chest pain), an abnormal laboratory finding (including results of blood tests, x-rays or scans) or a disease temporarily associated with the use of the protocol treatment, whether or not considered related to the investigational medicinal product. The number of participants who experienced at least 1 AE was reported for all participants in each treatment arm.</description>
        <time_frame>Up to 22 months</time_frame>
        <population>All randomized participants in Part 1 who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Part 1, participants received placebo IV as post-surgery therapy Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced At Least 1 Adverse Event (AE)</title>
          <description>An AE is defined as &quot;any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment&quot;. An AE can therefore be any unfavorable and unintended signs (such as rash or enlarged liver), symptoms (such as nausea or chest pain), an abnormal laboratory finding (including results of blood tests, x-rays or scans) or a disease temporarily associated with the use of the protocol treatment, whether or not considered related to the investigational medicinal product. The number of participants who experienced at least 1 AE was reported for all participants in each treatment arm.</description>
          <population>All randomized participants in Part 1 who received at least 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="475"/>
                    <measurement group_id="O2" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)</title>
        <description>An AE is defined as &quot;any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment&quot;. An AE can therefore be any unfavorable and unintended signs (such as rash or enlarged liver), symptoms (such as nausea or chest pain), an abnormal laboratory finding (including results of blood tests, x-rays or scans) or a disease temporarily associated with the use of the protocol treatment, whether or not considered related to the investigational medicinal product. The number of participants who discontinued study treatment due to an AE was reported for all participants in each treatment arm.</description>
        <time_frame>Up to 22 months</time_frame>
        <population>All randomized participants in Part 1 who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Part 1, participants received placebo IV as post-surgery therapy Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)</title>
          <description>An AE is defined as &quot;any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment&quot;. An AE can therefore be any unfavorable and unintended signs (such as rash or enlarged liver), symptoms (such as nausea or chest pain), an abnormal laboratory finding (including results of blood tests, x-rays or scans) or a disease temporarily associated with the use of the protocol treatment, whether or not considered related to the investigational medicinal product. The number of participants who discontinued study treatment due to an AE was reported for all participants in each treatment arm.</description>
          <population>All randomized participants in Part 1 who received at least 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL) of Pembrolizumab</title>
        <description>Blood samples were to be collected at pre-specified time points and plasma isolated for analysis of pembrolizumab CL, defined as the volume of plasma from which pembrolizumab is eliminated per unit time following IV pembrolizumab administration. Samples were not collected and this analysis was not performed.</description>
        <time_frame>Pre-dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and then Day 1 of cycle for every 4 cycles afterwards (up to approximately 16 months). Each cycle is 3 weeks.</time_frame>
        <population>As pre-specified by the protocol, pembrolizumab CL was not analyzed as planned and no data were collected since by the time of the interim analysis, pembrolizumab pharmacokinetics (PK) in melanoma patients had been well characterized and found to be consistent with the overall clinical pharmacology of pembrolizumab characterized across indications.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Part 1, participants received placebo IV as post-surgery therapy Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL) of Pembrolizumab</title>
          <description>Blood samples were to be collected at pre-specified time points and plasma isolated for analysis of pembrolizumab CL, defined as the volume of plasma from which pembrolizumab is eliminated per unit time following IV pembrolizumab administration. Samples were not collected and this analysis was not performed.</description>
          <population>As pre-specified by the protocol, pembrolizumab CL was not analyzed as planned and no data were collected since by the time of the interim analysis, pembrolizumab pharmacokinetics (PK) in melanoma patients had been well characterized and found to be consistent with the overall clinical pharmacology of pembrolizumab characterized across indications.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (V) of Pembrolizumab</title>
        <description>Blood samples were to be collected at pre-specified time points and plasma isolated for analysis of pembrolizumab V, defined as the theoretical volume that would be necessary to contain the total amount of administered pembrolizumab at the same concentration that it is observed in the blood plasma. Samples were not collected and this analysis was not performed.</description>
        <time_frame>Pre-dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and then Day 1 of cycle for every 4 cycles afterwards (up to approximately 16 months). Each cycle is 3 weeks.</time_frame>
        <population>As pre-specified by the protocol, pembrolizumab V was not analyzed as planned and no data were collected since by the time of the interim analysis, pembrolizumab PK in melanoma patients had been well characterized and found to be consistent with the overall clinical pharmacology of pembrolizumab characterized across indications.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Part 1, participants received placebo IV as post-surgery therapy Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (V) of Pembrolizumab</title>
          <description>Blood samples were to be collected at pre-specified time points and plasma isolated for analysis of pembrolizumab V, defined as the theoretical volume that would be necessary to contain the total amount of administered pembrolizumab at the same concentration that it is observed in the blood plasma. Samples were not collected and this analysis was not performed.</description>
          <population>As pre-specified by the protocol, pembrolizumab V was not analyzed as planned and no data were collected since by the time of the interim analysis, pembrolizumab PK in melanoma patients had been well characterized and found to be consistent with the overall clinical pharmacology of pembrolizumab characterized across indications.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Positive for Anti-Drug Antibodies (ADA) After Pembrolizumab Treatment</title>
        <description>Pre- and post-baseline serum samples from participants treated with pembrolizumab were analyzed for ADA by means of a neutralizing antibody assay which assessed the ability of ADA to block (neutralize) binding of pembrolizumab to Programmed Cell Death-1 (PD-1) protein. Overall immunogenicity was defined as the number of treatment emergent positive participants based on the total number of evaluable participants (treatment emergent positive, non-treatment emergent positive and negative immunogenicity status).</description>
        <time_frame>Pre-dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and then Day 1 of cycle for every 4 cycles afterwards (up to approximately 16 months). Each cycle is 3 weeks.</time_frame>
        <population>All randomized participants in Part 1 who had at least one ADA sample available after treatment with pembrolizumab and who had treatment emergent positive, non-treatment emergent positive, or negative immunogenicity status. Participants receiving Placebo treatment in Part 1 were not analyzed for ADA.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Part 1, participants received placebo IV as post-surgery therapy Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Positive for Anti-Drug Antibodies (ADA) After Pembrolizumab Treatment</title>
          <description>Pre- and post-baseline serum samples from participants treated with pembrolizumab were analyzed for ADA by means of a neutralizing antibody assay which assessed the ability of ADA to block (neutralize) binding of pembrolizumab to Programmed Cell Death-1 (PD-1) protein. Overall immunogenicity was defined as the number of treatment emergent positive participants based on the total number of evaluable participants (treatment emergent positive, non-treatment emergent positive and negative immunogenicity status).</description>
          <population>All randomized participants in Part 1 who had at least one ADA sample available after treatment with pembrolizumab and who had treatment emergent positive, non-treatment emergent positive, or negative immunogenicity status. Participants receiving Placebo treatment in Part 1 were not analyzed for ADA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Treatment emergent positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment emergent positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 29 months (through database cut-off date of 02-Oct-2017)</time_frame>
      <desc>All-Cause Mortality was reported for all randomized participants in Part 1.
Serious AEs and Other AEs were reported for all randomized participants who received at least 1 dose of study treatment in Part 1. Per protocol, disease progression of cancer on study was not considered an AE unless considered related to study drug. Therefore, MedDRA preferred terms &quot;Neoplasm progression&quot;, &quot;Malignant neoplasm progression&quot; and &quot;Disease progression&quot; not related to study drug are excluded as AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pembrolizumab</title>
          <description>In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>In Part 1, participants received placebo IV as post-surgery therapy Q3W.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="509"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Autoimmune pericarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Secondary adrenocortical insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Aptyalism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Autoimmune colitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="509"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Oral lichen planus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Papillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="509"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Infected seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Synovial rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Angiolipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="509"/>
                <counts group_id="E2" events="36" subjects_affected="25" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Benign lymph node neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of testis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Choroid melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Lentigo maligna</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Leydig cell tumour of the testis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="509"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Nodular melanoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="509"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Superficial spreading melanoma stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Autoimmune nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Glomerulosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug reaction with eosinophilia and systemic symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Lichenoid keratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="443" subjects_at_risk="509"/>
                <counts group_id="E2" subjects_affected="409" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="61" subjects_affected="52" subjects_at_risk="509"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="93" subjects_affected="75" subjects_at_risk="509"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="40" subjects_affected="37" subjects_at_risk="509"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="509"/>
                <counts group_id="E2" events="32" subjects_affected="29" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="238" subjects_affected="140" subjects_at_risk="509"/>
                <counts group_id="E2" events="234" subjects_affected="129" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="509"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="112" subjects_affected="88" subjects_at_risk="509"/>
                <counts group_id="E2" events="103" subjects_affected="73" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="55" subjects_affected="40" subjects_at_risk="509"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="93" subjects_affected="56" subjects_at_risk="509"/>
                <counts group_id="E2" events="71" subjects_affected="42" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="247" subjects_affected="168" subjects_at_risk="509"/>
                <counts group_id="E2" events="232" subjects_affected="168" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="73" subjects_affected="55" subjects_at_risk="509"/>
                <counts group_id="E2" events="47" subjects_affected="38" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="54" subjects_affected="44" subjects_at_risk="509"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="49" subjects_affected="39" subjects_at_risk="509"/>
                <counts group_id="E2" events="39" subjects_affected="30" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="509"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="69" subjects_affected="55" subjects_at_risk="509"/>
                <counts group_id="E2" events="64" subjects_affected="39" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="96" subjects_affected="63" subjects_at_risk="509"/>
                <counts group_id="E2" events="117" subjects_affected="82" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="40" subjects_affected="36" subjects_at_risk="509"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="130" subjects_affected="79" subjects_at_risk="509"/>
                <counts group_id="E2" events="98" subjects_affected="72" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="509"/>
                <counts group_id="E2" events="69" subjects_affected="54" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="35" subjects_at_risk="509"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="509"/>
                <counts group_id="E2" events="34" subjects_affected="30" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="509"/>
                <counts group_id="E2" events="38" subjects_affected="31" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="135" subjects_affected="95" subjects_at_risk="509"/>
                <counts group_id="E2" events="126" subjects_affected="93" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="88" subjects_affected="70" subjects_at_risk="509"/>
                <counts group_id="E2" events="66" subjects_affected="55" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="50" subjects_affected="46" subjects_at_risk="509"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="138" subjects_affected="99" subjects_at_risk="509"/>
                <counts group_id="E2" events="74" subjects_affected="58" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="90" subjects_affected="67" subjects_at_risk="509"/>
                <counts group_id="E2" events="51" subjects_affected="43" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="44" subjects_affected="27" subjects_at_risk="509"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="178" subjects_affected="74" subjects_at_risk="509"/>
                <counts group_id="E2" events="209" subjects_affected="77" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="509"/>
                <counts group_id="E2" events="37" subjects_affected="36" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All draft publications, including abstracts or detailed summaries of any proposed presentations, must be submitted to the Sponsor at the earliest practicable time for review, not less than 30 days before submission or presentation unless otherwise set forth in the clinical trial agreement. Sponsor shall have the right to delete any confidential information contained in any proposed presentation or abstract and may delay publication for up to 60 days for purposes of filing a patent application.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

